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Abstract
Introduction: Acetazolamide is commonly given to chronic obstructive pulmonary disease (COPD) patients with
metabolic alkalosis. Little is known of the pharmacodynamics of acetazolamide in the critically ill. We undertook the
pharmacodynamic modeling of bicarbonate response to acetazolamide in COPD patients under mechanical ventilation.
Methods: This observational, retrospective study included 68 invasively ventilated COPD patients who received one or
multiple doses of 250 or 500 mg of acetazolamide during the weaning period. Among the 68 investigated patients, 207
time-serum bicarbonate observations were available for analysis. Population pharmacodynamics was modeled using a
nonlinear mixedeffect model. The main covariates of interest were baseline demographic data, Simplified Acute
Physiology Score II (SAPS II) at ICU admission, cause of respiratory failure, co-prescription of drugs interfering with the
acid-base equilibrium, and serum concentrations of protein, creatinin, potassium and chloride. The effect of
acetazolamide on serum bicarbonate levels at different doses and in different clinical conditions was subsequently
simulated in silico.
Results: The main covariates interacting with acetazolamide pharmacodynamics were SAPS II at ICU admission
(P = 0.01), serum chloride (P < 0.001) and concomitant administration of corticosteroids (P = 0.02). Co-
administration of furosemide significantly decreased bicarbonate elimination. Acetazolamide induced a decrease in
serum bicarbonate with a dose-response relationship. The amount of acetazolamide inducing 50% of the putative
maximum effect was 117 ± 21 mg. According to our model, an acetazolamide dosage > 500 mg twice daily is
required to reduce serum bicarbonate concentrations > 5 mmol/L in the presence of high serum chloride levels or
coadministration of systemic corticosteroids or furosemide.
Conclusions: This study identified several covariates that influenced acetazolamide pharmacodynamics and could
allow a better individualization of acetazolamide dosing when treating COPD patients with metabolic alkalosis.
Keywords: COPD, mechanical ventilation, weaning, metabolic alkalosis
Introduction
Chronic obstructive pulmonary disease (COPD) is a lead-
ing cause of morbidity and mortality [1]. The natural his-
tory of the disease is marked by exacerbations that affect
the prognosis of patients with COPD [2]. Noninvasive
mechanical ventilation in the clinical setting of COPD
exacerbations reduces mortality [3]. However, initiation of
invasive mechanical ventilation may be necessary, for
instance, after the failure of an initial trial of noninvasive
mechanical ventilation. Weaning from mechanical ventila-
tion can be particularly difficult and prolonged in COPD
patients with severe preexisting airflow limitation [4].
Metabolic alkalosis is an acid-base disorder that occurs
frequently in the critically ill [5]. Metabolic alkalosis
leads to hypoventilation, which may cause difficulty in
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the weaning process. Metabolic alkalosis is characterized
by an elevated serum pH level secondary to increased
plasma bicarbonate (HCO3
-) retention. Correction of
this acid-base disorder increases both minute ventilation
and partial pressure of oxygen (PaO2), potentially allow-
ing COPD patients to be weaned more rapidly from
mechanical ventilation [6,7]. Acetazolamide (ACET),
when administered after proper fluid loading and potas-
sium supplementation, is one of the most common drugs
used to treat metabolic alkalosis. ACET decreases proxi-
mal tubular HCO3
- reabsorption through carbonic anhy-
drase (CA) inhibition in the luminal borders of renal
proximal tubule cells [8]. In addition, ACET (1) induces
CO2 retention by inhibiting CA isoenzymes in red cells
and tissue and (2) improves cardiac function and gas
exchange in cor pulmonale by stimulating diuresis [8].
There is a paucity of literature to support only one
ACET dosing strategy during the weaning period for
mechanically ventilated COPD patients. It has been estab-
lished that a single 500-mg daily dose of ACET reverses
metabolic alkalosis over 72 hours in intubated patients
with COPD or asthma as effectively as multiple doses of
250 mg [9]. However, a recent study has shown that ACET
administration at a daily dose of 500 mg during the wean-
ing period of COPD patients with mixed or pure metabolic
alkalosis only moderately diminishes serum HCO3
- levels,
without changing either partial pressure of carbon dioxide
(PaCO2) levels or minute ventilation [10]. The lack of effec-
tiveness of ACET on respiratory mechanics could be due
to alterations in ACET pharmacodynamics [10]. Indeed,
ACET pharmacodynamics in ICU patients has received lit-
tle attention, especially in mechanically ventilated COPD
patients.
The objectives of our present study were to develop a
population pharmacodynamic model for ACET in
mechanically ventilated COPD patients using nonlinear
mixed-effects modeling and to examine the possible effect
of covariates on a pharmacodynamic parameter, the
observed serum HCO3
- level.
Materials and methods
Data for COPD patients admitted to the medical ICU of a
tertiary care teaching hospital with the diagnosis of acute
respiratory failure were retrospectively examined over a
10-year period (2000 to 2010). In accordance with French
law, no local institutional review board authorization was
needed, owing to the study’s observational design, and the
Commission Nationale de l’Informatique et des Libertés
approved the use of computerized medical data with pro-
tection of patient confidentiality. COPD patients intubated
for acute respiratory failure who had received ACET
during the weaning period were eligible for analysis.
COPD was diagnosed according to the Global Initiative
for Chronic Obstructive Lung Disease criteria [11]. The
weaning period was defined as the time between readiness
to wean and extubation. Readiness to wean was defined
according to the criteria of the Sixth International Confer-
ence Consensus in Intensive Care Medicine held in 2005
on the subject of weaning from mechanical ventilation
[12]. Five hundred and thirty-six files of COPD patients
admitted to our ICU were examined.
ACET administration
Acetazolamide (Diamox; Sanofi-Aventis, Paris, France)
administration (250 to 500 mg delivered two times per day
via nasogastric tube or intravenously) was monitored by
physicians in charge of the patient according to arterial
blood gas analyses routinely performed. ACET was not
administered to patients with liver or kidney failure.
Patient data
Baseline demographic data at the time of ICU admission
included patient age, sex, body weight, smoking history,
use of long-term systemic corticosteroids or diuretics
(including ACET), home oxygen therapy or home nonin-
vasive ventilation, left ventricular ejection fraction assessed
by echocardiography and prior pulmonary function tests
performed while the patient was in stable condition, the
Simplified Acute Physiology Score II (SAPS II) [13] and
the cause of respiratory failure. Serum HCO3
- level was
obtained by arterial blood gas analysis (ABL series; Radio-
meter Copenhagen, Copenhagen, Denmark) before and up
to 24 hours after ACET administration. Serum levels of
protein, creatinine, potassium and chloride were recorded
during the three hours preceding ACET administration
and up to 24 hours afterward. Throughout ACET treat-
ment, data regarding the mode of mechanical ventilation
and additional treatments which could alter acid-base
equilibrium (furosemide, corticosteroids, b2-agonists and
fluid loading) were collected from charts prospectively
completed by physicians and nurses. We also collected
length of invasive mechanical ventilation, length of ICU
stay and ICU outcome. Among the parameters appraised,
serum HCO3
- concentration was used in this pharmacody-
namic analysis for direct relationship with ACET dosage.
Weaning from mechanical ventilation
The weaning process was standardized by implementing a
written protocol according to the recommendations of the
Consensus Conference of the Société de Réanimation de
Langue Française held in October 2001. The weaning
strategy (1) consisted of a progressive decrease in pressure
support ventilation or volume-assisted ventilation with the
use of progressively increased time on a T-piece and (2)
was chosen by physicians in charge according to the diffi-
culty of the weaning process [12]. External positive end-
expiratory pressure (PEEP) was applied to counterbalance
intrinsic PEEP, typically 4 to 6 cmH2O, in COPD patients.
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During the weaning process, b2-agonists or furosemide
was administered by attending physicians as indicated. In
our ICU, the criteria for extubation were also standardized
in a written protocol detailed elsewhere [10].
Pharmacodynamic modeling
The pharmacokinetics of ACET were ascribed to a one-
compartment open model with linear elimination [14,15].
Elimination half-life was fixed at six hours (0.25 hours/
day) [14]. The corresponding differential equations used
were for the intravenous or enteral route, respectively:
dA(t)/dt = −kelim × A(t)
or
dG(t)/dt = −ka ×G(t), with dA(t)/dt = ka × G(t)− ke lim × A(t),
where A(t) and kelim, respectively, denote the ACET
amount in the body at a given time and the constant
rate of elimination (half-life = 0.693/kelim), and G(t) and
ka represent the ACET amount in the gut at a given
time and the first-order absorption rate, respectively.
Serum HCO3
- concentration (Bicar(t), in mmol/L) was
ascribed to a turnover model as follows:
dBicar(t)/dt = kin − kout × Bicar(t),
where kin (mmol/L/day) and kout (day
-1) are the
HCO3
- rate formation and the first-order constant rate
of HCO3
- elimination, respectively. At equilibrium, dBi-
car/dt = 0 and the HCO3
- baseline level was Bicar0 =
kin/kout. The effect of ACET (EACET) on HCO3
- equili-
brium was assumed to increase the elimination process:
dBicar(t)/dt = kin − EACET × kout × Bicar(t),
with EACET = 1 + Emax × A(t)/[A(t) + A50],
where A50 is ACET dosage that induces 50% of the
maximal effect (Emax).
Data analysis
Data was analyzed using the nonlinear mixed-effect mod-
eling software program Monolix version 3.1S Release 2
http://wfn.software.monolix.org/. The main covariates of
interest were baseline demographic data, SAPS II at ICU
admission, cause of respiratory failure, coprescription of
drugs interfering with the acid-base equilibrium and
serum concentrations of protein, creatinine, potassium
and chloride. Parameters were estimated by computing
the maximum likelihood estimation of the parameters
without any approximation of the model (that is, no line-
arization) using the stochastic approximation expectation
maximization algorithm combined with a Markov chain
Monte Carlo procedure. A proportional error model was
used to describe residual variability (εPROP and εADD), and
between-subject variability (BSV, or h) was ascribed to an
exponential error model. Parameter shrinkage was calcu-
lated as [1 - sd(h)/ω], where sd(h) and ω are the standard
deviation of individual h parameters and the population
model estimate of the BSV, respectively. Standard errors
were computed by stochastic approximation, not by line-
arization. The likelihood ratio test, including the log-likeli-
hood, the Akaike information criterion (AIC) and the
Bayesian information criterion (BIC), were used to test dif-
ferent hypotheses regarding the final model, the covariate
effects on pharmacokinetic parameters, the residual varia-
bility model (proportional versus proportional plus addi-
tive error model) and the structure of the variance-
covariance matrix for the BSV parameters. Residuals are
presented as normalized prediction distribution errors
(NPDEs), based on the estimates of unbiased means and
variances of the predictions by using 500 Monte Carlo
simulations of the final model. (The calculation includes a
decorrelation step of the prediction errors.) The mean
values and variance of these normalized residues must not
be different from 0 and 1, respectively. Diagnostic graphics
and other statistics were derived using the R software pro-
gram [16]. The results are expressed as raw numbers (%),
means ± SD or medians (ranges) for data with nonnormal
distributions. P < 0.05 was considered significant.
Results
Of the 536 COPD patients identified, 446 patients
received neither invasive mechanical ventilation nor
ACET during their ICU stay. The files of 22 patients
were incomplete and therefore were excluded. Sixty-
eight patients were eligible for analysis. Patients’ charac-
teristics upon entry into the study are summarized in
Table 1. None of the included patients received ventila-
tion through a tracheostomy tube. Among the 68 inves-
tigated patients, 207 time-serum HCO3
- observations
were available for analysis, with a median of three obser-
vations per patient (range, 1 to 6). Differences between
the pre-ACET dose HCO3
- and HCO3
- levels at 24
hours in all patients, plotted according to the total
dosage of ACET administered (Figure 1), showed a
dose-response relationship. Additionally, the scale of
observed differences was similar to what has previously
been reported [9,10].
Pharmacodynamic modeling
The turnover model satisfactorily described the data. The
parameters of the model were Bicar0 (baseline), kout and
A50. BSVs could be estimated for Bicar0 and kout only. It
was not possible to simultaneously determine the Emax
and A50 parameters. We therefore decided to assign Emax
a value of 1. Residual variability was described by a pro-
portional error model. Using the enteral route of ACET
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administration to predict serum HCO3
- concentration did
not improve the model or the precision of the other para-
meters. Since the biodisponibility of ACET is excellent,
the simplest pharmacokinetic (intravenous) model was
therefore used for all patients. The main covariate effects
on Bicar0 were SAPS II at ICU admission (P = 0.01),
serum chloride concentration (P < 0.001) and concomitant
glucocorticoid administration (P = 0.02). Coadministration
of furosemide significantly decreased HCO3
- elimination
(effect on kout). The final covariate submodel was then:
Bicar0 = TV(Bicar0)×(SAPS II/50)
−0.11
×(chloride/100)−1.17×(1.1 if glucocorticoids)
and
kout = TV(kout)× [1− furosemie dosage/(furosemide dosage + Fur50)],
Table 1 Main characteristics of the study population (N = 68)a
Characteristics Value
Age, years, median (range) 74 (44 to 99)
Male/female gender, n (%) 40 (58.9)/28 (41.1)
Smoker, pack-years, median (range) 50 (10 to 130)
Ex-smoker, n (%) 46 (67.6)
Diuretic treatment more than four weeks, n (%) 21 (30.9)
Systemic corticosteroid treatment more than four weeks, n (%) 5 (7.3)
Home oxygen therapy, n (%) 26 (38.2)
Home noninvasive ventilation, n (%) 6 (8.8)
Body weight, kg, median (range) 61.8 (34 to 142)
FEV1, mL, median (range) 800 (350 to 1940)
FEV1/FVC, %, median (range) 50.9 (24 to 66)
LVEF, %, median (range) 60 (20 to 80)
SAPS II at ICU admission, median (range) 47 (20 to 95)
Lenght of ICU stay, days, median (range) 21 (6 to 123)
Length of invasive mechanical ventilation, days, median (range) 18 (3 to 110)
ICU mortality, n (%) 16 (23.5)
Cause of respiratory failure
Pneumonia, n (%) 22 (32.4)
Bronchitis, n (%) 17 (25)
Left ventricular failure, n (%) 5 (7.3)
Surgery, n (%) 4 (5.9)
Use of sedative drugs, n (%) 6 (8.8)
Pulmonary embolism, n (%) 1 (1.5)
Unknown, n (%) 13 (19.1)
Laboratory measurements before onset ACET administration
pH, median (range) 7.45 (7.34 to 7.57)
PaCO2, mmHg, median (range) 55 (36 to 93)
PaO2, mmHg, median (range) 78 (41 to 136)
Serum bicarbonate, mmol/L, median (range) 37.5 (27 to 58)
Serum potassium, mmol/L, median (range) 3.8 (2.7 to 4.6)
Serum chloride, mmol/L, median (range) 96 (69 to 108)
Serum protein, g/L, median (range) 57 (40 to 72)
Serum creatinine, μmol/L, median (range) 64 (22 to 202)
Additional treatments during ACET administration
Furosemide, n (%) 32 (47.1)
Systemic glucocorticoid, n (%) 10 (14.7)
b2-agonists, n (%) 8 (11.7)
Fluid load, mL, median (range) 1, 000 (0 to 2, 300)
Pressure-support ventilation, n (%) 31 (45.6)
Volume-assisted ventilation, n (%) 37 (54.4)
aACET, acetazolamide; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; LVEF, left
ventricular ejection fraction; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen; SAPS II, Simplified Acute Physiology Score II.
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where TV is typical value and Fur50 denotes the dose
of furosemide that induces a 50% decrease of kout. The
AIC/BIC ratio was 1, 044/1, 066. When parameters
were standardized to a SAPS II of 50 and a serum chlor-
ide level of 100 mmol/L, the dose of ACET provoking
50% of the putative maximal effect on serum HCO3
-
(A50) was 117 +/- 21 mg. Additionally, we checked the
likelihood profile of A50, confirming that the value of
A50 was not 0 (data not shown). Table 2 summarizes
the final population pharmacokinetic estimates. The
predicted versus observed serum HCO3
- concentrations
are depicted in Figures 2A, B and 2C, which show the
corresponding normalized prediction distribution error
tests for these data. The normalized prediction distribu-
tion error test plotted against the covariates of interest
was also satisfactory, illustrating the robustness of the
model (data not shown). A graph of the model errors
over time was created by plotting measured model pre-
dicted values and measured individual predicted values
over time for each subject. No systematic deviation of
error was obvious over time (data not shown).
ACET dosing in COPD patients
Using this pharmacodynamic model, we assessed the
effect of ACET administered once daily on serum
HCO3
- levels under various conditions of serum chlor-
ide level and coprescription of furosemide or glucocorti-
coids (Figures 3A, B and 3C). According to our model, a
higher ACET dosage is required to reduce serum HCO3
-
concentration > 5 mmol/L in the presence of high levels
of serum chloride or coprescription of systemic corticos-
teroids or furosemide.
Discussion
Little is known about the pharmacokinetics or pharmaco-
dynamics of ACET in acutely ill patients, especially COPD
patients during the weaning process [17]. At low doses (4
mg/kg), ACET preferentially and fully inhibits renal and
endothelial cell CA [18,19], whereas at higher doses (7 to
12 mg/kg), ACET inhibits the activity of CA in red blood
cells, chemoreceptors and respiratory muscles [19]. These
findings underline the complexity of the response to
ACET [8,20]. Morover, ACET administration is associated
with almost no severe side effects. ACET administered at
the usual dosage to COPD patients during the weaning
process is known to induce a modest but significant
Table 2 Parameter estimates of the final acetazolamide population model in patients with chronic obstructive
pulmonary disease (N = 68)a
Parameter Estimate (%rse) BSV (%rse) [shrinkage]
Half-life, day 0.25 (fixed) NA
Bicar0, mmol/L 35.5 (2) 0.101 (9) [0.04]
× SAPS II effect (SAPS II/50)-0.11 -0.112 (39)
× Corticosteroid effect, if present 1.092 (41)
× Serum chloride effect (chloride/100) -1.17 -1.18 (17)
kout, mmol/day 0.395 (17) 0.792 (15) [0.27]
Fur50 187 (21)
A50 117 (18) NA
Residual variability 0.04 (8) NA
a%rse, percentage relative standard error; ACET, acetazolamide; A50, ACET dosage that provokes 50% of putative maximal effect on serum bicarbonate; BSV,
between-subject variability; Bicar0, bicarbonate baseline level; Fur50: furosemide dose that induces a 50% decrease of kout; kout, first-order constant rate of
bicarbonate elimination; NA, not applicable; SAPS II, Simplified Acute Physiology Score II; TV: typical value. When COPD patients received ACET, the effect of
covariates on observed serum bicarbonate levels was Bicar0 = TV(Bicar0) × (SAPS II/50)
-0.11 × (chloride/100)-1.17 × (1.1 if glucocorticoids) and kout = TV(kout) × [1 -
furosemide dosage/(furosemide dosage + Fur50)]. Shrinkage was calculated as [1 - sd(h)/ω], where sd(h) and ω are the standard deviation of individual h
parameters and the population model estimate of the BSV, respectively.
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Figure 1 Differences between pre-acetazolamide dose
bicarbonate level and bicarbonate level at 24 hours in all
patients, plotted according to the total dosage of
acetazolamide administered. Boxplots show the medians, first and
third quartiles and 10th and 90th percentiles. The zero level at
predose indicates that these values are based on intrapatient
differences (repeated measures). Predose values: median 37.5; 25th
and 75th percentiles 34 and 41, respectively; and 10th and 90th
percentiles 30 and 45 mmol/L, respectively.
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Figure 2 Goodnees-of-fit plots for the final model of
acetazolamide pharmacodynamics. Shown are the results for 68
weaning chronic obstructive pulmonary disease patients. Observed
versus model-predicted serum bicarbonate concentrations for (A)
mean and (B) individual predictions and (C) normalized prediction
distribution errors (NPDEs) versus predicted serum bicarbonate
concentrations. The solid lines represent the identity lines and the
dotted lines represent the regression lines. The mean and variance
of the NPDE distribution were not significantly different from 0 and
1, respectively (P = 0.66 and P = 0.60, respectively; Wilcoxon signed-
rank test and Fisher variance test, respectively) and from normality
(P = 0.052, Shapiro-Wilks test), illustrating the robusteness of serum
bicarbonate prediction after acetazolamide administration.
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Figure 3 Model-predicted effect of 125 mg, 250 mg, 500 mg or
1, 000 mg of acetazolamide. Shown are the effects of
acetazolamide (ACET) administered once daily on serum
bicarbonate in the presence of (A) low or high levels of serum
chloride, (B) coprescription or not of 20 to 160 mg/day furosemide
or (C) coprescription or no coprescription of 1 mg/kg/day systemic
cortocosteroids. Modelization of ACET pharmacodynamics was
derived from 68 chronic obstructive pulmonary disease patients
during the weaning period with metabolic alkalosis (Simplified
Acute Physiology Score II at ICU admission was standardized at 50
and is shown in all parts of the figure). A higher ACET dosage is
required to reduce serum bicarbonate concentrations > 5 mmol/L
when high chloride or coprescription of systemic corticosteroids or
furosemide occurs.
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decrease in serum HCO3
- concentration [10]. Higher
doses of the drug could therefore be given to mechanically
ventilated COPD patients to improve clinical respiratory
variables. Our study is the first, to the best of our knowl-
edge, to use population pharmacodynamic modeling to
characterize the dose-response relationship associated
with ACET response in invasively ventilated COPD
patients. None of the patients included in this study
experienced undesirable side effects after ACET adminis-
tration, confirming the relative safety of the drug.
ACET is commonly used to treat metabolic alkalosis.
ACET inhibits the CA enzyme and induces metabolic
acidosis [8]. Metabolic acidosis in turn induces an
increase in both minute ventilation and PaO2, potentially
allowing COPD patients to be weaned more rapidly from
mechanical ventilation [6,7]. We therefore decided to use
serum HCO3
- concentration as a substitute for the effect
of ACET, taking into account parameters that might
influence HCO3
- concentration over time.
In our model, the Emax parameter could not be esti-
mated, probably because of a lack of data with high
enough concentrations. With a 117-mg dose of ACET
that produces a putative half-maximal effect, this model
predicts that a dosage of ACET > 500 mg twice daily
could decrease serum HCO3
- concentration > 5 mmol/L
in the presence of high serum chloride concentration or
coadministration of furosemide or corticosteroids. The
main covariates that had an effect on ACET pharmacody-
namics were SAPS II at ICU admission, serum concen-
tration of chloride and the coadministration of
corticosteroids or furosemide. The dosage based on these
parameters is expected to improve the benefits of ACET
in COPD patients with metabolic alkalosis.
We showed that few covariates affected ACET pharma-
codynamics in mechanically ventilated COPD patients.
Both furosemide and corticosteroids induce metabolic
alkalosis by stimulation (by different mechanisms) of distal
tubular H+ secretion [21]. Higher doses of ACET may be
needed to counterbalance the effect of these drugs. Addi-
tionally, ACET and furosemide are transported by the
same carrier-mediated mechanism from plasma to their
site of action localized at the luminal side of renal tubules
[22]. Furosemide may therefore decrease the cotransport
of ACET by a competitive mechanism. Our results are of
import, since many COPD patients are treated by corticos-
teroids or furosemide. Indeed, half the population in our
study received furosemide during the weaning period.
Chloride and HCO3
- are the two major anions in the
serum. Physicochemical principles of conservation of mass
and electroneutrality imply that a high serum chloride
concentration is likely to be associated with a relatively
low HCO3
- concentration. In the presence of a higher
chloride concentration (and thus a lower HCO3
- concen-
tration), non-CA-dependent mechanisms of HCO3
-
reabsorption becomes activated and contributes to a
greater extent in HCO3
- reclamation when the total fil-
tered HCO3
- falls [23-25].
The role of SAPS II on ACET pharmacodynamics
remains speculative. The SAPS II includes the serum level
of HCO3
- at ICU admission. We hypothesize that the
most severely ill COPD patients at ICU admission may
have a higher respiratory acidotic component of alkalosis
at readiness to wean, limiting the effect of 500 mg of
ACET [10].
The single biggest factor affecting ACET elimination is
renal clearance. In our model, serum creatinine was not a
significant covariate, probably because none of our
patients had severe renal impairment. However, renal
function is embedded in the SAPS II, which is a covariate
of interest in our model. Additionally, the ACET dosage
derived from our model are only valid if an elimination
half-life of ACET of six hours is assumed. Our model
therefore cannot be used to describe the pharmacody-
namics of ACET in patients with kidney failure. Lastly, the
volume of distribution of HCO3
- is approximately that of
total body water. Body weight as a substitute for total
body water was not found to affect the response to ACET
in our model.
In a recent case-control study, we showed that ACET
given at the dosage of 500 mg/day significantly but moder-
ately diminished serum HCO3
- without otherwise effecting
arterial blood gases (except for the PaO2/fraction of
inspired O2 ratio) or respiratory parameters in weaning
COPD patients [10]. Taken together, these findings indi-
cate that, during the weaning period, COPD patients
could benefit from a higher ACET dosage for effective
reversal of metabolic alkalosis.
We show here that in mechanically ventilated COPD
patients there is a dose-response relationship after
administration of ACET to decrease serum HCO3
-, with
a putative half-maximal effective dose of 117 mg. Berthel-
sen and colleagues [17], in a study of heavily sedated
alkalotic patients, showed that increasing doses of ACET
were associated with increased excretion of urinary
HCO3
- over a short period of time. Our results differ
from those reported in several previous studies. Mazur
and colleagues [9] showed that ACET administered as a
single 500-mg dose reversed metabolic alkalosis in
mechanically ventilated patients as effectively as four
administrations of 250 mg, suggesting that there is no
dose-response relationship when using ACET. Similarly,
we did not find a relationship between preexisting
respiratory function (including baseline forced expiratory
volume in one second) and response to ACET adminis-
tration in acutelly ill COPD patients, contrary to pre-
viously published data derived from more stable COPD
patients [8,26]. The discrepancy between our results
and those reported in previous studies are likely due to
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differences in illness severity at admission, serum chlor-
ide levels at admission and coprescription of corticoster-
oids or furosemide.
One of the limitations of this study is that patients at
a single center were included. Our patient population
was nonetheless comparable to similar COPD patients
treated with invasive mechanical ventilation [27].
Another possible limitation is that some patients pre-
sented compensated respiratory acidosis without real
overlapping metabolic alkalosis, reflecting the variety
of acid-base disorders present in mechanically venti-
lated COPD patients [10]. To the best of our knowl-
edge, the pH range observed in the present study has
not yet been reported to influence CA inhibition by
ACET.
Conclusions
In conclusion, an increased ACET dosage could be ben-
eficial in the treatment of COPD patients receiving cor-
ticosteroids or furosemide or presenting with high
serum chloride concentrations. These assumptions
should be prospectively confirmed, since our conclu-
sions are drawn on the basis of studying only 68
patients. Unanswered questions remain, such as the
effect of ACET administration on PaCO2 levels and
minute ventilation in these patients. Finally, the effect of
ACET administration on COPD patients in terms of
mortality and length of mechanical ventilation remains
to be determined.
Key messages
• Little is known about the pharmacodynamics of ACET
in the critically ill.
• We used a population pharmacodynamic model to
characterize the dose-response relationship associated
with ACET response in invasively ventilated COPD
patients.
• According to our model, an ACET dosage > 500 mg
twice daily is required to reduce serum HCO3
- concen-
trations by > 5 mmol/L in the presence of high serum
chloride concentrations or coadministration of furose-
mide or corticosteroids.
Abbreviations
%rse: percentage relative standard error; A50: ACET dosage that induces 50%
of the maximal effect; ACET: acetazolamide; AIC: Akaike information criterion;
A(t): ACET amount in the body; BIC: Bayesian information criterion; Bicar(t):
serum bicarbonate level; Bicar0, bicarbonate baseline level; BSV: between-
subject variability; CA: carbonic anhydrase; COPD: chronic obstructive
pulmonary disease; EACET: ACET effect; Emax: maximal effect of ACET; FEV1:
forced expiratory volume in one second; Fur50: dose of furosemide that
induces a 50% decrease of kout; FVC: forced vital capacity; G(t): ACET amount
in gut; HCO3
-: bicarbonate; ka: first-order absorption rate; kelim: constant rate
of elimination; kin: bicarbonate rate formation; kout: first-order constant rate
of bicarbonate elimination; LVEF: left ventricular ejection fraction; NA, not
applicable; SAPS II: Simplified Acute Physiology Score II; TV: typical value.
Acknowledgements
The authors thank Virginie Fulda and Agnès Lillo-Le Louët for their help in
collecting data.
The funding sources were the Medical Intensive Care Unit, Hôpital Européen
Georges Pompidou, and the Centre d’Investigation Clinique-0991, Institut
national de la santé et de la recherche médicale (Inserm), Assistance
Publique, Hôpitaux de Paris, University Paris Descartes, Paris, France.
Author details
1Medical Intensive Care Unit, European Georges Pompidou Hospital (AP-HP),
Université Paris Descartes, Sorbonne Paris Cité, 20 rue Leblanc, 75908 Paris,
France. 2CIC-0109 Cochin-Necker Inserm, Unité de Recherche Clinique,
Tarnier Hospital, (AP-HP) and E.A. 3620 Université Paris Descartes, Sorbonne
Paris Cité, 27 Rue du Faubourg Saint-Jacques 75014 Paris, France.
Authors’ contributions
NH collected data and drafted the manuscript. CF conceived of the study,
participated in its design and coordinated and drafted the manuscript. SU
analyzed the data and drafted the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 15 May 2011 Revised: 6 July 2011
Accepted: 14 September 2011 Published: 14 September 2011
References
1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V,
Buist S: Chronic obstructive pulmonary disease: current burden and
future projections. Eur Respir J 2006, 27:397-412.
2. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, Sahin I,
Kizkin O: Factors affecting survival of hospitalised patients with COPD.
Eur Respir J 2005, 26:234-241.
3. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS: Non-invasive positive
pressure ventilation to treat respiratory failure resulting from
exacerbations of chronic obstructive pulmonary disease: Cochrane
systematic review and meta-analysis. BMJ 2003, 326:185.
4. Gursel G: Determinants of the length of mechanical ventilation in
patients with COPD in the intensive care unit. Respiration 2005, 72:61-67.
5. Khanna A, Kurtzman NA: Metabolic alkalosis. Respir Care 2001, 46:354-365.
6. Berthelsen P, Gøthgen I, Husum B, Jacobsen E: Oxygen uptake and carbon
dioxide elimination after acetazolamide in the critically ill. Intensive Care
Med 1985, 11:26-29.
7. Brimioulle S, Berre J, Dufaye P, Vincent JL, Degaute JP, Kahn RJ:
Hydrochloric acid infusion for treatment of metabolic alkalosis
associated with respiratory acidosis. Crit Care Med 1989, 17:232-236.
8. Swenson ER: Carbonic anhydrase inhibitors and ventilation: a complex
interplay of stimulation and suppression. Eur Respir J 1998, 12:1242-1247.
9. Mazur JE, Devlin JW, Peters MJ, Jankowski MA, Iannuzzi MC, Zarowitz BJ:
Single versus multiple doses of acetazolamide for metabolic alkalosis in
critically ill medical patients: a randomized, double-blind trial. Crit Care
Med 1999, 27:1257-1261.
10. Faisy C, Mokline A, Sanchez O, Tadié JM, Fagon JY: Effectiveness of
acetazolamide for reversal of metabolic alkalosis in weaning COPD
patients from mechanical ventilation. Intensive Care Med 2010, 36:859-863.
11. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y,
Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J, Global Initiative for
Chronic Obstructive Pulmonary Disease: Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease:
GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
12. Boles JM, Bion J, Connors A, Herridge M, Marsh B, Melot C, Pearl R,
Silverman H, Stanchina M, Vieillard-Baron A, Welte T: Weaning from
mechanical ventilation. Eur Respir J 2007, 29:1033-1056.
13. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology
Score (SAPS II) based on a European/North American multicenter study.
JAMA 1993, 270:2957-2963.
14. Yano I, Takayama A, Takano M, Inatani M, Tanihara H, Ogura Y, Honda Y,
Inui K: Pharmacokinetics and pharmacodynamics of acetazolamide in
patients with transient intraocular pressure elevation. Eur J Clin
Pharmacol 1998, 54:63-68.
Heming et al. Critical Care 2011, 15:R213
http://ccforum.com/content/15/5/R213
Page 8 of 9
15. Ritschel WA, Paulos C, Arancibia A, Agrawal MA, Wetzelsberger KM,
Lücker PW: Pharmacokinetics of acetazolamide in healthy volunteers
after short- and long-term exposure to high altitude. J Clin Pharmacol
1998, 38:533-539.
16. Ihaka R, Gentleman R: R: a language for data analysis and graphics.
J Comput Graphic Stat 1996, 5:299-314.
17. Berthelsen P, Gøthgen I, Husum B, Jacobsen E: Dissociation of renal and
respiratory effects of acetazolamide in the critically ill. Br J Anaesth 1986,
58:512-516.
18. Teppema L, Dahan A: Acetazolamide and breathing: Does a clinical dose
alter peripheral and central CO2 sensitivity? Am J Resp Crit Care Med 1999,
160:1592-1597.
19. Kiwull-Schöne HF, Teppema LJ, Kiwull PJ: Low-dose acetazolamide does
affect respiratory muscle function in spontaneously breathing
anesthetized rabbits. Am J Respir Crit Care Med 2001, 163:478-483.
20. Wagenaar M, Teppema L, Berkenbosch A, Olievier C, Folgering H: The
effect of low-dose acetazolamide on the ventilatory CO2 response curve
in the anaesthetized cat. J Physiol 1996, 495:227-237.
21. Webster NR, Kulkarni V: Metabolic alkalosis in the critically ill. Crit Rev Clin
Lab Sci 1999, 36:497-510.
22. Uway Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of
thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic
anion transporter rOAT1. J Pharmacol Exp Ther 2000, 295:261-265.
23. Maren TH: Chemistry of the renal reabsorption of bicarbonate. Can J
Physiol Pharmacol 1974, 52:1041-1050.
24. Maren TH: Carbonic anhydrase: chemistry, physiology, and inhibition.
Physiol Rev 1967, 47:595-781.
25. Preisig PA, Toto RD, Alpern RJ: Carbonic anhydrase inhibitors. Ren Physiol
1987, 10:136-159.
26. Skatrud JB, Dempsey JA: Relative effectiveness of acetazolamide versus
medroxyprogesterone acetate in correction of chronic carbon dioxide
retention. Am Rev Respir Dis 1983, 127:405-412.
27. Groenewegen KH, Scholas AM, Wouters EF: Mortality and mortality-related
factors after hospitalization for acute exacerbation of COPD. Chest 2003,
124:459-467.
doi:10.1186/cc10448
Cite this article as: Heming et al.: Population pharmacodynamic model
of bicarbonate response to acetazolamide in mechanically ventilated
chronic obstructive pulmonary disease patients. Critical Care 2011 15:
R213.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Heming et al. Critical Care 2011, 15:R213
http://ccforum.com/content/15/5/R213
Page 9 of 9
